BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares. Sentiment for ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

Don’t slouch or allow your spine to round while sitting. Placing your computer screen at eye level can make it easier to sit ...

About Myriad Genetics Myriad Genetics is a leading molecular diagnostics testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

The global personal genome testing market is on a remarkable growth trajectory, projected to soar to USD 4,468 million by 2032, up from USD 1,545.5 million in 2022. This growth reflects a robust CAGR ...

Researchers urged hospitals to set up processes for updating pharmacogenomic results, but it's unclear how frequently that ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price lowered by Scotiabank from $24.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a ...

In the preceding three months, 10 analysts have released ratings for Myriad Genetics MYGN, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the ...